Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

JERUSALEM, Feb. 7, 2017  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 13-14, 2017 […]

Categories: Press Releases|Tags: |

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017

JERUSALEM, Nov. 29, 2016  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company’s proprietary […]

Categories: Press Releases|Tags: |

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $29.5 Million in payments from HTIT received to date

JERUSALEM, October 6, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator of Technologies […]

Categories: Press Releases|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, September 19, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place September 20-22, 2016 in Las Vegas. David […]

Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 7, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 18th Annual Global Investment Conference, taking place September […]

Categories: Press Releases|Tags: |

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $25.5 M in payments from HTIT received to date

JERUSALEM, August 2, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received a milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. […]

Categories: Press Releases|Tags: |

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

JERUSALEM, July 28, 2016 /PRNewswire/ —

Statistically Significant Results Across Key Glycemic Endpoints 

Conference Call Today at 11:00 AM ET 

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today reported additional data from the recently concluded Phase IIb trial […]

Categories: Press Releases|Tags: |

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

JERUSALEM, July 26, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director.

“We are very pleased to welcome Dr. Eldor on […]

Categories: Press Releases|Tags: |

Oramed Announces $6.5 Million Milestone Payment from HTIT

Payment comes in wake of positive topline phase IIB results

JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone […]

Categories: Press Releases|Tags: |

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

JERUSALEM, June 9, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented […]

Categories: Press Releases|Tags: |